A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a major medical journal demonstrates that while overweight people often shed a large proportion of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying such drugs should be cognizant of the potential of fast weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment mass in about 18 months.
Comparing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through dieting typically have a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Doctors believe the way of the drugs explains the accelerated rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the long-term character of excess weight," akin to managing diseases like high blood pressure.
Patient Testimonies
People who have discontinued the jabs report a powerful resurgence of cravings.
"I experienced a switch flipping and you're instantly extremely hungry," recalled an individual.
This difficulty is worsened if individuals have not developed lasting lifestyle or habit changes during therapy.
Significant Use
Survey data show that millions of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is higher among females than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are potent tools for shedding pounds, they are not a magic solution and maintained weight loss relies on integrated behavioural management.
